
Jay Karri, MD, MPH
@jaykarrimd
Interventional Pain and PM&R physician @UMMC.
Clinical interests: #MedEd, #Spine, #MSKUS.
Not medical advice. Views/opinions my own.
ID: 1148573684950609925
09-07-2019 12:44:40
645 Tweet
1,1K Followers
1,1K Following






Patient with 3 months of left-sided pain in L3 distribution but w/o motor/sensory deficits. MRI shows an L3/4 disc herniation...that is anterior, with no central canal, lateral recess, or foraminal compromise. I encounter this once a year. Thoughts and insights? James Noake



Resident and Fellows Ultrasound course was so great! Thank you Jay Karri, MD, MPH Dmitri Souza Scott Pritzlaff Dr. Chai and Dr. Singh for taking the time to educate the future! #ASRAFALL24 ASRA Pain Medicine



Fantastic work by Heather Jackson, PhD, APRN, FAANP and Katherine Cloud! The "Fundamentals of Excellent Pain Management Care" program was outstanding and drew a large, diverse, and engaged audience. ASRA Pain Medicine #ASRAFALL24



Healio spoke with Ryan D'Souza, MD of Mayo Clinic about study data showing that more than 40% of patients with cancer treated with chemotherapy develop persistent peripheral nerve pain. #CIPN #Chemotherapy bit.ly/41Ab6C2

🚨Time to rethink the SCS trial-to-implant ratio?🚨 With recent implant rates >80%, are trial-to-implant ratios are still meaningful? Or is it time to update utilization metrics to include explant and per-capita ratios? Eellan Sivanesan, MD, FASA Ryan D'Souza, MD bit.ly/3QSdihN

In this editorial Jay Karri, MD, MPH and colleagues discuss Suzetrigine, a novel non-opioid analgesic targeting Nav1.8, that has recently gained FDA approval for moderate-to-severe acute pain. Read the full article here: bit.ly/44bIb8K Ryan D'Souza, MD

Suzetrigine, a novel non-opioid analgesic, has recently gained FDA approval for moderate-to-severe acute pain. While offering hope amid the opioid crisis, its ambiguous clinical benefits and trial limitations raise scrutiny. Jay Karri, MD, MPH Ryan D'Souza, MD bit.ly/44bIb8K